June 7, 2022 7:56am
After a negative sector close and a more than weak aftermarket
Pre-open indications: 4 Upside Indications, 3 Downside Indications, 1 Sell into Strength, 1 Puff/Pump/Promote
RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
The 8;00 A.M., ET edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are DOWN -0.68% (-225 points), S&P futures are DOWN -0.81% (-33 points) and NASDAQ futures are DOWN -1.08% (-136 points) early in the pre-open – so far,
Stock futures declined Tuesday anticipating a negative open,
European stocks also declined,
Asia-Pacific shares were mixed, as all three global markets struggled for direction
Henry’omics:
Stock futures are dipping Tuesday after a sleepy day of trading as investors await key inflation data due out later in the week.
All three of the major averages finished slightly higher Monday.
RegMed Investors’ (RMi) closing bell: “we are in a danger zone of sector share pricing as news doesn’t affect hop-scotching sentiment. Market inclines as cell and gene therapy sector declines; what did I write Friday, “Waiting for next week’s declines” - it’s happening!” … https://www.regmedinvestors.com/articles/12461
Ebb and flow –
Q2/22 –
June – 2 positive and 2 negative close
· May - 11 positive and 10 negative closes
· April - 1 holiday, 6 positive and 13 negative closes
Q1/22:
· March – 13 negative and 10 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Exhibiting positive indication:
Verve Therapeutics (VERV) closed down -$1.04 to $33.54 <52-week low of $11.30 and a high of $78.00> after Friday’s -$0.10 with a positive +$0.09 or +0.66% aftermarket indication,
Chinook Therapeutics (KDNY) closed down -$1.05 to $16.38 after Friday’s +$1.41, Thursday’s -$1.41, Wednesday’s -$1.39 and last Tuesday’s -$0.45 with positive +$0.81 or +4.95% pre-open indication,
Mesoblast (MESO) closed down -$0.26 to $3.06 <52-week low of $3.03> after Friday’s -$0.09 with a positive +$0.13 or +4.25% pre-open indication,
Editas Medicine (EDIT) closed down -$0.32 to $11.59 after Friday’s +$0.37, Thursday’s +$0.57, Wednesday’s -$0.42 and Tuesday’s -$0.29 with a positive +$0.11 or +0.95% pre-open indication,
Exhibiting negative indications:
Ultragenyx (RARE) closed down -$2.15 to $49.26 <52-week low of $45.20> with a negative -$0.40 or -0.81% pre-open indication,
Beam Therapeutics (BEAM) closed down -$1.39 to $35.89 <52-week low of $27.77> after Friday’s -$0.43 with a negative -$0.09 or -0.25% pre-open indication,
CRISPR Therapeutics (CRSP) closed up +$0.01 to $64.22 with a negative -$1.22 or -1.90% pre-open indication,
Puff/Pump and Promote: Maintaining SELL
Biostage (OTCQB: BSTG) closed up +$0.23 to $4.68 with 3,575 shares traded after Friday’s -$0.33 with 250 shares traded, Thursday’s flat with 1 share traded, Wednesday’s -$0.37 to $4.75 with 100 shares traded and last Tuesday’s -$0.22 with 330 shares traded having traded with six (6 – May 20 to May 27) sessions being flat.
- WARNING: Earnings reported a VERY SAD picture of a company’s status without U.S investors and reliance on non-U.S. Chinese investors. Another PPM -private placement – this one for $5.1 M without a price per share notification. Also, the terminal death lawsuit just got settled (4/28) for $6 M with a PPM – a preferred convertible debt financing. is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?
· So, Has BSTG filed its Annual Report to the FDA, isn’t it a “Material Fact”?
The BOTTOM LINE: Sentiment was largely muted Monday … as Investors are still assessing whether the sector has reached a bottom from this year’s sell-off.
Great quote, “Since the beginning of the year we’re seeing an altitude sickness when you look at the valuation multiple,” said Ed Yardeni, president at Yardeni Research.
The positive, "We're seeing the continued evolution of cell-based therapy in cancer and visibility on advances that’ll make these approaches mainstream and more impactful" – Dr. Scott Gottlieb
Again, as have I written (repeatedly), “There's a battle in the cell and gene therapy sector between which or what breaks first: share pricing resilience or tumbling into yet another downturn as fear remains beneath the strength of any positive close” …
I am not always right but, more than frequently not wrong … I just DO NOT trust this market … too much fear and panic. This continuing state of volatility confirms fears that I have been expressing in these daily and weekly posts.
What changes …
I have NOT seen ANY step-up of declining company investment by ANY CEOs and their management teams – WHY NOT?
I try to keep it simple … and short!
I caution investors that the severe share pricing’s – technical and fundamental damage has been suffered these past several months which will take longer than a few good sessions to repair.
Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
